Citizens Financial Group Inc. RI Has $950,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Citizens Financial Group Inc. RI increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,942 shares of the medical instruments supplier’s stock after purchasing an additional 157 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Becton, Dickinson and Company were worth $950,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Cetera Investment Advisers increased its holdings in shares of Becton, Dickinson and Company by 380.8% in the first quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock valued at $14,580,000 after purchasing an additional 46,668 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Becton, Dickinson and Company by 15.6% during the first quarter. Canada Pension Plan Investment Board now owns 280,193 shares of the medical instruments supplier’s stock worth $69,334,000 after buying an additional 37,851 shares in the last quarter. M&G Plc boosted its position in shares of Becton, Dickinson and Company by 0.9% in the second quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock valued at $165,967,000 after acquiring an additional 6,052 shares during the period. Benson Investment Management Company Inc. increased its position in Becton, Dickinson and Company by 13.2% during the third quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock worth $5,380,000 after acquiring an additional 2,602 shares during the period. Finally, Swedbank AB boosted its holdings in Becton, Dickinson and Company by 1.8% in the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock valued at $36,367,000 after purchasing an additional 2,729 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BDX shares. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $224.00 on Friday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89. The stock has a market cap of $64.74 billion, a PE ratio of 37.71, a PEG ratio of 1.66 and a beta of 0.43. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The firm’s fifty day moving average price is $235.15 and its two-hundred day moving average price is $234.56.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period last year, the firm posted $3.42 earnings per share. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.86%. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.